Genetics and Family Risk in PFBC
At a Glance
PFBC can be inherited through dominant or recessive gene variants, but inheriting a variant does not guarantee symptoms. Genetic counseling can clarify inheritance, explain uncertain or negative results, and support decisions about family testing and reproductive planning.
Understanding why Primary Familial Brain Calcification (PFBC) runs in some families while affecting individuals differently starts with the genes. Genetic testing can often identify a specific “typo” in your DNA that caused the condition, but it is important to remember that having a genetic variant does not always mean you will feel sick [1][2].
How PFBC is Inherited
PFBC can be passed down in two different ways, depending on which gene is involved. This pattern determines the risk for your children, siblings, and other relatives [3][4].
- Autosomal Dominant (AD): This is the most common form. It means you only need to inherit one copy of the “typo” gene (from either parent) to be at risk for the condition [3]. The genes associated with this pattern include SLC20A2, PDGFRB, PDGFB, and XPR1 [3][5]. In these families, each child of an affected person has a 50% chance of inheriting the gene variant, not a 50% chance of developing symptoms.
- Autosomal Recessive (AR): This form is less common and usually occurs when a person inherits two copies of the “typo” gene—one from each parent [3][6]. The parents are usually “carriers” who do not have the disease themselves. The genes for this pattern include MYORG, JAM2, and NAA60 [7][8]. In these families, if both biological parents are carriers, each child has a 25% chance of inheriting both copies. The risk is different when one parent is affected or the partner’s carrier status is unknown.
Imaging vs. Clinical Penetrance: The Great Variable
One of the most confusing parts of PFBC genetics is penetrance—the likelihood that a person with the gene will actually show signs of the disease [9].
- Imaging Penetrance: This refers to whether calcification shows up on a brain scan. For dominant genes like SLC20A2, imaging penetrance is reported in some studies as nearly 100%, meaning almost everyone with the gene will eventually have “spots” on their CT scan [9][1].
- Clinical Penetrance: This refers to whether a person actually develops symptoms, like movement or mood changes. Clinical penetrance is much lower, estimated in a pooled review at roughly 61% across the most common genes [9].
These are research estimates from specific cohorts, not predictions of your personal future. This means it is very common to have a family member who “tests positive” on a brain scan but feels completely healthy [10][11]. For example, about 54% of people with a PDGFRB variant in one cohort never develop clinical symptoms [1].
Genetic Counseling and Testing for Families
Deciding whether to test family members who have no symptoms (asymptomatic relatives) is a deeply personal choice. There is no universally established schedule for imaging or testing asymptomatic relatives. The 2025 international consensus guidelines emphasize that genetic counseling should be a core part of your care [4].
A genetic counselor can help your family navigate:
- The “VUS” Challenge: Sometimes testing finds a Variant of Uncertain Significance (VUS)—a genetic change that we don’t yet understand. A VUS should not be used to make medical decisions or to diagnose relatives [12][11].
- Negative Results: A negative panel does not exclude PFBC. A substantial proportion of clinically suggestive cases remain genetically unresolved, as not all causative genes are known [4].
- Reproductive Planning: For people considering having children, understanding whether their PFBC is dominant or recessive can help clarify the risks for future generations [3][6].
- The Impact of Knowing: Since there is currently no “cure” that stops calcification, some family members may prefer not to know their status, while others find the information empowering for their future health planning. Testing decisions should consider privacy, insurance, and psychosocial implications where relevant [13][4].
Current guidelines recommend using comprehensive next-generation sequencing (or even whole-genome sequencing) to get the clearest picture of your family’s genetic landscape, usually guided by your genetic counselor [4].
Common questions in this guide
If I have a PFBC gene variant, will I develop symptoms?
How can PFBC be passed from a parent to a child?
What does a VUS mean on a PFBC genetic test?
Can a negative genetic test rule out PFBC?
Should relatives without symptoms have PFBC genetic testing or brain scans?
What type of genetic testing is used to investigate PFBC in a family?
Questions For You
Answer a question to get research tailored to you. Your answers are private.
Get notified when new evidence is published on Bilateral striopallidodentate calcinosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific gene was identified in my genetic test, and is it inherited in an autosomal dominant or recessive pattern?
- 2.Is the genetic variant found in my family classified as 'pathogenic' or a 'variant of uncertain significance' (VUS)?
- 3.Given my genetic results, what is the exact percentage risk for my children or siblings to inherit this gene?
- 4.If a relative has a brain scan showing calcification but no symptoms, how often should they be monitored by a neurologist?
- 5.Can you refer my family members to a genetic counselor who has experience with neurogenetic conditions like PFBC?
References
References (13)
- 1
Genotype-Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review.
Balck A, Schaake S, Kuhnke NS, et al.
Movement disorders : official journal of the Movement Disorder Society 2021; (36(11)):2468-2480 doi:10.1002/mds.28753.
PMID: 34432325 - 2
Primary familial brain calcifications: genetic and clinical update.
Westenberger A, Balck A, Klein C
Current opinion in neurology 2019; (32(4)):571-578 doi:10.1097/WCO.0000000000000712.
PMID: 31157644 - 3
Basal ganglia calcification: 'Fahr's disease'.
Magrinelli F, Jesuthasan A, Bhatia KP, Batla A
Practical neurology 2025; (25(6)):520-526 doi:10.1136/pn-2024-004258.
PMID: 40169250 - 4
Primary Brain Calcification: An International Consensus on Nomenclature, Diagnosis, Evaluation, and Management.
Luo W, Cen Z, Koek H, et al.
Movement disorders : official journal of the Movement Disorder Society 2026; (41(2)):315-336 doi:10.1002/mds.70140.
PMID: 41346103 - 5
Characterization of XPR1/SLC53A1 variants located outside of the SPX domain in patients with primary familial brain calcification.
López-Sánchez U, Nicolas G, Richard AC, et al.
Scientific reports 2019; (9(1)):6776 doi:10.1038/s41598-019-43255-x.
PMID: 31043717 - 6
Rare Presentation of Homozygous SLC20A2 Mutations Causing Intra-Arterial Cerebral Vasculopathy and Stroke in Infancy: Case Report and Review of the Literature.
Baker L, Hadid F, Irshaidat SS, et al.
Case reports in genetics 2025; (2025()):1587968 doi:10.1155/crig/1587968.
PMID: 41458256 - 7
Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification.
Schottlaender LV, Abeti R, Jaunmuktane Z, et al.
American journal of human genetics 2020; (106(3)):412-421 doi:10.1016/j.ajhg.2020.02.007.
PMID: 32142645 - 8
Biallelic NAA60 variants with impaired n-terminal acetylation capacity cause autosomal recessive primary familial brain calcifications.
Chelban V, Aksnes H, Maroofian R, et al.
Nature communications 2024; (15(1)):2269 doi:10.1038/s41467-024-46354-0.
PMID: 38480682 - 9
Primary familial brain calcification with known gene mutations: a systematic review and challenges of phenotypic characterization.
Tadic V, Westenberger A, Domingo A, et al.
JAMA neurology 2015; (72(4)):460-7 doi:10.1001/jamaneurol.2014.3889.
PMID: 25686319 - 10
Underestimated disease prevalence and severe phenotypes in patients with biallelic variants: A cohort study of primary familial brain calcification from China.
Chen S, Cen Z, Fu F, et al.
Parkinsonism & related disorders 2019; (64()):211-219 doi:10.1016/j.parkreldis.2019.04.009.
PMID: 31003906 - 11
Novel likely pathogenic SLC20A variant in primary familial brain calcification.
Sharma R, Stitt D
BMJ case reports 2022; (15(3)) doi:10.1136/bcr-2021-245909.
PMID: 35236675 - 12
Primary brain calcification: an international study reporting novel variants and associated phenotypes.
Ramos EM, Carecchio M, Lemos R, et al.
European journal of human genetics : EJHG 2018; (26(10)):1462-1477 doi:10.1038/s41431-018-0185-4.
PMID: 29955172 - 13
The clinical and genetic spectrum of primary familial brain calcification.
Carecchio M, Mainardi M, Bonato G
Journal of neurology 2023; (270(6)):3270-3277 doi:10.1007/s00415-023-11650-0.
PMID: 36862146
This page explains PFBC inheritance and genetic testing for educational purposes, not as personal medical advice. A genetic counselor and neurologist can help interpret your results and family risks.